These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 11857034)

  • 1. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A; McDonnell TJ; Meyn RE
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
    Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation.
    Eid MA; Lewis RW; Abdel-Mageed AB; Kumar MV
    Int J Oncol; 2002 Jul; 21(1):111-7. PubMed ID: 12063557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
    Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
    Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N; El-Deiry WS
    Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria from TRAIL-resistant prostate cancer cells are capable of responding to apoptotic stimuli.
    Liang Y; Eid MA; Lewis RW; Kumar MV
    Cell Signal; 2005 Feb; 17(2):243-51. PubMed ID: 15494215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
    Yamaguchi K; Uzzo RG; Pimkina J; Makhov P; Golovine K; Crispen P; Kolenko VM
    Oncogene; 2005 Sep; 24(38):5868-77. PubMed ID: 15897871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
    Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.